DRGEM announced on the 14th that it achieved consolidated sales of 57.2 billion KRW and an operating profit of 6.2 billion KRW in the first half. These represent a year-on-year growth of 13.3% and 33.9%, respectively. This result was driven by expanded overseas sales and product mix improvements. The operating profit margin rose by approximately 1.7 percentage points to 10.9%. In the second quarter, sales reached 29.9 billion KRW and operating profit reached 3.5 billion KRW. Notably, these increased by 10.0% and 23.4%, respectively.
■ Key Drivers of Growth and Global Market Expansion
The improvement in performance was driven by the growth of the digital radiography (DR) market and stable sales of the main General DR products. Increasing overseas demand and an improved product mix, resulting from an expanded revenue share of system products, contributed to enhanced profitability.
DRGEM is maintaining stable sales in major existing markets such as North America and Europe. At the same time, it is strengthening its push into emerging markets including South America and Asia. DRGEM plans to expand sales in regions with high demand for digital X-ray conversion.
■ Growth Strategy and Expanded Portfolio for H2
DRGEM plans to continue its earnings growth in the second half of the year. Notably, a 19.3 billion KRW medical equipment supply contract in Turkey will begin impacting 2026 Financial Results H1 from the third quarter. DRGEM is expected to broaden its overseas market share by expanding its product portfolio with RAYMO, a new mobile X-ray system that received FDA clearance and CE certification in the first half. In addition, PROVUE, an AI-based C-Arm X-ray system, is scheduled for release in the second half. Additionally, DRGEM plans to initiate its ultrasound business by leveraging its global partner channel of over 300 distributors across more than 130 countries.
DRGEM plans to expand its business scope in the medium term to include industrial X-ray equipment, other medical devices, and new software, thereby strengthening its competitiveness as a digital medical imaging solutions provider.
“Our first-half performance demonstrates both DRGEM’s product competitiveness and profitability in the global market,” said DRGEM. “We will diversify our revenue structure through new product launches and business initiatives, while establishing sustainable growth momentum through quality competitiveness and cost reduction.”
*Attachment. Financial Performance Summary: H1 2026 (Unit KRW).
| Type | H1 26 | H1 25 | YoY |
|---|---|---|---|
| Revenue | 57.2B | 50.5B | +13.3% |
| Operating Profit | 6.2B | 4.63B | +33.9% |
| Operating Margin | 10.9% | 9.2% | +1.7%p |
| Net Profit | 7.6B | 2.07B | +267.2% |
